Combination Therapy with an SGLT2 Inhibitor as Initial Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis.

Tamara Y MilderSophie L StockerChristina Abdel ShaheedLucy McGrath-CadellDorit Samocha-BonetJerry R GreenfieldRichard Osborne Day

Published in: Journal of clinical medicine (2019)

Initial SGLT2 inhibitor/metformin combination therapy has glycaemic and weight benefits compared with either agent alone and appears relatively safe. High dose SGLT2 inhibitor/metformin combination therapy appears to have modest weight, but no glycaemic benefits compared with the low dose combination therapy.

Keyphrases

combination therapy
type diabetes
high dose
low dose
body mass index
weight loss
physical activity
weight gain
glycemic control
stem cell transplantation
insulin resistance
metabolic syndrome
body weight
skeletal muscle